{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:38:16Z","timestamp":1788982696456,"version":"build-2803163510"},"reference-count":21,"publisher":"Jaypee Brothers Medical Publishing","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAPI"],"published-print":{"date-parts":[[2022,11,7]]},"abstract":"<jats:p>Background: Tuberculosis (TB) can have manifestations closely mimicking autoimmune diseases.  The prevalence of autoantibodies in TB varies among different populations. Objectives: To study the prevalence of anti-neutrophilic cytoplasmic antibodies (ANCA) and  antinuclear antibodies (ANA) in pulmonary tuberculosis (PTB). Methods: This was a cross-sectional, observational study. Subjects with microbiologically confirmed  PTB, either via smear or culture positivity on sputum or bronchoalveolar lavage (BAL) fluid, or  positive rapid diagnostic tests were included. ANCA against proteinase-3 (PR3), myeloperoxidase  (MPO), lactoferrin, and elastase were tested using an enzyme-linked immunosorbent assay (ELISA).  ANA was detected using indirect immunofluorescence (IIF). Results: Eighty-nine subjects with a median [interquartile range (IQR)] age of 28 (20\u201346)  years, 67.4% males, were recruited. Eighty-one subjects had microbiological confirmation  on sputum examination, and eight required examination of BAL fluid. Sera were drawn from  62 treatment-na\u00efve subjects, the rest (27) were on antitubercular therapy (ATT). Eighty-six (96.6%)  subjects tested positive for anti-elastase antibody, seven of which were also positive for anti-PR3.  None were positive for anti-MPO and anti-lactoferrin. Six (6.7%) subjects tested positive for ANA.  None of the subjects had features of underlying connective tissue disease or vasculitis. Conclusion: PTB patients showed a high prevalence of anti-elastase and a low prevalence of ANA  and anti-PR3 antibodies. ANCA positivity should be interpreted with caution in TB endemic areas.  The role of anti-elastase antibodies in differentiating TB from ANCA-associated vasculitis (AAV)  needs further research.<\/jats:p>","DOI":"10.5005\/japi-11001-0126","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T10:11:15Z","timestamp":1667470275000},"page":"62-64","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of Antineutrophil Cytoplasmic Antibodies and Antinuclear Antibodies in Patients with Pulmonary Tuberculosis: A Tertiary Care Center Experience from North India"],"prefix":"10.59556","volume":"70","author":[{"given":"Yogesh","family":"Chander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupoor","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GSRSNK","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Minz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digambar","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"ref-1","unstructured":"India TB Report 2018 [Internet]. [cited 2019 Dec 15]. Available from: ht tps:\/\/tbcindia.gov.in\/WriteReadData\/l892s\/6250311444TB%20India%20Report%202018.pdf"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Dayal L, Choi J, Shammash J. Distinguishing vasculitis from TB: a diagnostic challenge in differentiating granulomatosis with polyangiitis f rom TB. Chest 2016;150(4):1073A.","DOI":"10.1016\/j.chest.2016.08.1180"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Bossuyt X, Cohen Tervaert J-W, Arimura Y, et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017;13(11): 683-692.","DOI":"10.1038\/nrrheum.2017.140"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Sharma A, Naidu GSRSNK, Rathi M, et al. Clinical features and long-term outcomes of 105 granulomatosis with polyangiitis patients: a single center experience from north India. Int J Rheum Dis 2018;21(1):278-284.","DOI":"10.1111\/1756-185X.13071"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Mittal S, Naidu GSRSNK, Jha S, et al. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis\u2014a real-life experience. Clin Rheumatol 2021;40(2):645-651.","DOI":"10.1007\/s10067-020-05261-7"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1-11.","DOI":"10.1002\/art.37715"},{"key":"ref-7","unstructured":"Pradhan VD, Badakere SS, Ghosh K, et al. Spectrum of anti-neutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis overlaps with that of Wegener's granulomatosis. Indian J Med Sci 2004;58(7):283-288."},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Flores-Su\u00e1rez LF, Cabiedes J, Villa AR, et al. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology 2003;42(2): 223-229.","DOI":"10.1093\/rheumatology\/keg066"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Lima I, Oliveira RC, Cabral MS, et al. Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis. Rheumatol Int 2014;34(9):1231-1234.","DOI":"10.1007\/s00296-014-3009-z"},{"key":"ref-10","unstructured":"Rapoport BL, Morrison RCA, Sher R, et al. A study of autoantibodies in chronic mycobacterial infections. Int J Lepr 1990;58(3):518-525."},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Cheng MP, Butler-Laporte G, Parkes LO, et al. Prevalence of auto-antibodies in pulmonary tuberculosis. Open Forum Infect Dis 2019;6(4): ofz114.","DOI":"10.1093\/ofid\/ofz114"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Talor MV, Stone JH, Stebbing J, et al. Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 2007;150(1):42-48.","DOI":"10.1111\/j.1365-2249.2007.03453.x"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Savige J, Davies D, Falk RJ, et al. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000;57(3):846-862.","DOI":"10.1046\/j.1523-1755.2000.057003846.x"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Mahr A, Batteux F, Tubiana S, et al. Brief report: prevalence of antineutrophi l cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol 2014;66(6):1672-1677.","DOI":"10.1002\/art.38389"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Adebajo AO, Charles P, Maini RN, et al. Autoantibodies in malaria, tuberculosis and hepatitis B in a West African population. Clin Exp Immunol 1993;92(1):73-76.","DOI":"10.1111\/j.1365-2249.1993.tb05950.x"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Medina F, Camargo A, Moreno J, et al. Anti-neutrophil cytoplasmic autoantibodies in leprosy. Br J Rheumatol 1998;37(3):270-273.","DOI":"10.1093\/rheumatology\/37.3.270"},{"key":"ref-17","unstructured":"Sherkat R, Mos tafavizadeh K, Zeydabadi L, et al. Antineutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis. Iran J Immunol 2011;8(1):52-57."},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Teixeira L, Mahr A, Jaureguy F, et al. Low seroprevalence and poor specificity of antineutrophilcy toplasmic antibodies in tuberculosis. Rheumatology 2005;44(2):247-250.","DOI":"10.1093\/rheumatology\/keh467"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Elkayam O, Bendayan D, Segal R, et al. The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. Rheumatol Int 2013;33(4):949-953.","DOI":"10.1007\/s00296-012-2487-0"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Rothfield NF, Bierer WF, Garfield JW. Isoniazid induction of antinuclear antibodies: a prospective study. Ann Intern Med 1978;88(5):650-652.","DOI":"10.7326\/0003-4819-88-5-650"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Vedove CD, Del Giglio M, Schena D, et al. Drug-induced lupus erythematosus. Arch Dermatol Res 2009;301(1):99-105.","DOI":"10.1007\/s00403-008-0895-5"}],"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:56:43Z","timestamp":1745578603000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/files\/JAPI0126_p62-64_compressed.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,1]]},"published-print":{"date-parts":[[2022,11,7]]}},"URL":"https:\/\/doi.org\/10.5005\/japi-11001-0126","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}